文献速递肿瘤 PET/CT核素与放射性配体治疗

Nectin-4靶向[68Ga]Ga-FZ-NR-1 PET/CT对比[18F]FDG在复发或转移性三阴性乳腺癌中的预后价值与诊断效能

Prognostic value and diagnostic performance of nectin-4-targeted [68Ga]Ga-FZ-NR-1 PET/CT versus [18F]FDG in recurrent or metastatic triple-negative breast cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-09-12

本研究纳入40例复发或转移性三阴性乳腺癌患者,在1周内分别行[68Ga]Ga-FZ-NR-1与[18F]FDG PET/CT,比较诊断效能并分析预后价值。结果显示[68Ga]Ga-FZ-NR-1 PET/CT检出更多病灶,灵敏度和特异度均优于[18F]FDG,且基线MTV40和HI可预测生存。

要点

  • [68Ga]Ga-FZ-NR-1 PET/CT灵敏度98.13%、特异度68.63%,均优于[18F]FDG。
  • Nectin-4表达存在高瘤内空间异质性,中位病灶间倍差3.10。
  • 基线MTV40高预测更短PFS,HI高预测更短OS。

核心结论

  • [68Ga]Ga-FZ-NR-1 PET/CT在复发或转移性TNBC中诊断效能优于[18F]FDG并具独立预后价值。
  • 这些假设生成性发现提示其有潜力作为无创影像生物标志物用于风险分层和Nectin-4靶向治疗患者筛选。

研究设计与样本

  • 临床转化研究,纳入40例复发或转移性TNBC患者。
  • 患者在1周内接受[68Ga]Ga-FZ-NR-1与[18F]FDG PET/CT检查。
  • 诊断效能比较采用McNemar检验,生存分析采用Kaplan-Meier法。

主要发现

  • [68Ga]Ga-FZ-NR-1 PET/CT显示Nectin-4表达存在高瘤内空间异质性,中位病灶间倍差3.10,中位变异系数31.70%。
  • [18F]FDG的SUVmax更高,但[68Ga]Ga-FZ-NR-1在各转移部位获得显著更高的靶本比。
  • [68Ga]Ga-FZ-NR-1 PET/CT检出更多病灶,灵敏度98.13% vs. 93.46%,特异度68.63% vs. 27.45%。
  • 基线平均MTV40([68Ga]Ga-FZ-NR-1)高预测更短PFS(P = 0.009)。
  • 基线HI([68Ga]Ga-FZ-NR-1)高预测更短OS(P = 0.008)。

关键数值与推荐

  • [68Ga]Ga-FZ-NR-1 PET/CT灵敏度98.13%、特异度68.63%;[18F]FDG PET/CT灵敏度93.46%、特异度27.45%。
  • 中位病灶间倍差3.10,中位变异系数31.70%([68Ga]Ga-FZ-NR-1)。
  • 高基线平均MTV40([68Ga]Ga-FZ-NR-1)预测更短PFS,P = 0.009。
  • 高基线HI([68Ga]Ga-FZ-NR-1)预测更短OS,P = 0.008。

临床怎么用

  • 对复发或转移性TNBC患者,[68Ga]Ga-FZ-NR-1 PET/CT可能提供优于[18F]FDG的病灶检出与诊断准确性。
  • 基线[68Ga]Ga-FZ-NR-1 PET/CT的MTV40和HI可用于辅助风险分层。
  • 该显像有望用于筛选适合Nectin-4靶向治疗的患者,但需进一步验证。

局限性

  • 研究为假设生成性临床转化研究,样本量40例。
  • 结论需更大规模研究验证后方可常规用于风险分层与治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nectin-4 has emerged as an attractive diagnostic and therapeutic target in a wide range of malignancies. Herein, we aimed to evaluate the clinical utility of a novel Nectin-4-targeted radiotracer, [68Ga]Ga-FZ-NR-1, for non-invasive whole-body mapping, head-to-head diagnostic comparison with [18F]FDG, and survival prediction in recurrent or metastatic triple-negative breast cancer (TNBC). METHODS: 40 patients with recurrent or metastatic TNBC who underwent [68Ga]Ga-FZ-NR-1 and [18F]FDG PET/CT within 1 week were enrolled in this clinical translational study. Diagnostic performance was compared using the McNemar test. The survival analyses were performed using the Kaplan-Meier method. RESULTS: [68Ga]Ga-FZ-NR-1 PET/CT revealed high intra-patient spatial heterogeneity of Nectin-4 expression, yielding a median inter-lesion fold difference of 3.10 and a median coefficient of variation of 31.70%. Although a higher SUVmax was observed with [18F]FDG, [68Ga]Ga-FZ-NR-1 achieved a significantly higher tumor-to-background ratio across various metastatic sites. Therefore, [68Ga]Ga-FZ-NR-1 PET/CT detected more lesions than [18F]FDG PET/CT and showed better sensitivity and specificity (98.13% vs.93.46% and 68.63% vs. 27.45%, respectively). Furthermore, high baseline mean MTV40 ([68Ga]Ga-FZ-NR-1) and HI ([68Ga]Ga-FZ-NR-1) predicted significantly shorter progression-free survival (P = 0.009) and overall survival (P = 0.008), respectively. CONCLUSION: [68Ga]Ga-FZ-NR-1 PET/CT demonstrates improved diagnostic performance and independent prognostic value compared to [18F]FDG in recurrent or metastatic TNBC. These hypothesis-generating findings suggest that it holds potential as a non-invasive imaging biomarker to aid future risk stratification and patient selection for Nectin-4-targeted therapies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li Y, Sun Y, Sun L, et al. Prognostic value and diagnostic performance of nectin-4-targeted [68Ga]Ga-FZ-NR-1 PET/CT versus [18F]FDG in recurrent or metastatic triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42730763. doi:10.1007/s00259-026-08177-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。